Proven Results with ILARIS

ILARIS® is the first and only once-monthly injection that is FDA approved for the treatment of Familial Mediterranean Fever (FMF). This FDA approval was based on research that included 181 children and adults with Periodic Fever Syndromes.

ILARIS helps provide fast and sustained symptom relief

In a clinical study, patients with FMF were given ILARIS and evaluated for a complete response. A complete response meant that at day 15 and throughout the entire 16-week treatment period, they had minimal or no disease activity.

Study participants were assessed for their CRP* measurements and given a Physician's Global Assessment (PGA) score. The PGA is a 5-point scale used to evaluate the overall disease severity of a patient.

*CRP: C-reactive protein is a blood test to measure inflammation in the body.

Each patient's PGA score was based on several signs and symptoms, including:

Rash

Rash

Abdominal and/or Chest Pain

Abdominal and/or
Chest Pain

Joint Inflammation

Joint Inflammation

The following percentage of people with FMF achieved a complete response at day 15 and throughout the entire 16-week treatment period.

0%

61.3% of FMF patients had minimal or no disease activity just 15 days after their first dose of ILARIS
61.3% of FMF patients had minimal or no disease activity just 15 days after their first dose of ILARIS

61.3% of FMF patients had minimal or no disease activity at Day 15 through Week 16 of the study.
(n=19/31)

61.3% of FMF patients had minimal or no disease activity at Day 15 through Week 16 of the study.
(n=19/31)

Talk to a doctor about whether ILARIS may be right for your child.

Next: Safety Considerations